10,240 Shares in Edwards Lifesciences Corporation $EW Purchased by NTV Asset Management LLC

NTV Asset Management LLC purchased a new stake in shares of Edwards Lifesciences Corporation (NYSE:EW) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 10,240 shares of the medical research company’s stock, valued at approximately $884,000.

Several other hedge funds have also made changes to their positions in EW. Fifth Third Wealth Advisors LLC boosted its stake in Edwards Lifesciences by 1.8% in the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 7,268 shares of the medical research company’s stock worth $627,000 after purchasing an additional 132 shares during the period. NorthRock Partners LLC grew its position in Edwards Lifesciences by 1.0% during the 2nd quarter. NorthRock Partners LLC now owns 16,191 shares of the medical research company’s stock worth $1,465,000 after purchasing an additional 153 shares in the last quarter. Elevation Wealth Partners LLC grew its position in Edwards Lifesciences by 24.8% during the 3rd quarter. Elevation Wealth Partners LLC now owns 779 shares of the medical research company’s stock worth $67,000 after purchasing an additional 155 shares in the last quarter. Plan A Wealth LLC raised its stake in Edwards Lifesciences by 3.0% during the 3rd quarter. Plan A Wealth LLC now owns 5,460 shares of the medical research company’s stock valued at $471,000 after purchasing an additional 158 shares during the period. Finally, Premier Path Wealth Partners LLC raised its stake in Edwards Lifesciences by 4.4% during the 1st quarter. Premier Path Wealth Partners LLC now owns 3,880 shares of the medical research company’s stock valued at $311,000 after purchasing an additional 162 shares during the period. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Performance

EW stock opened at $89.15 on Monday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.77 and a current ratio of 4.52. The stock has a market cap of $51.33 billion, a P/E ratio of 51.23, a P/E/G ratio of 2.33 and a beta of 0.87. The firm has a 50 day simple moving average of $88.05 and a 200 day simple moving average of $86.65. Edwards Lifesciences Corporation has a 52 week low of $74.66 and a 52 week high of $96.29.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The firm had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.70 billion. During the same period in the previous year, the firm posted $0.67 earnings per share. The firm’s revenue was up 13.6% on a year-over-year basis. Research analysts anticipate that Edwards Lifesciences Corporation will post 3.00 earnings per share for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, SVP Andrew M. Dahl sold 544 shares of Edwards Lifesciences stock in a transaction on Monday, August 31st. The shares were sold at an average price of $91.06, for a total transaction of $49,536.64. Following the completion of the sale, the senior vice president owned 14,868 shares of the company’s stock, valued at $1,353,880.08. This trade represents a 3.53% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, VP Daniel J. Lippis sold 619 shares of the business’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total transaction of $56,966.57. Following the transaction, the vice president owned 40,034 shares in the company, valued at approximately $3,684,329.02. This represents a 1.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 5,045 shares of company stock worth $451,596. 0.31% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on EW shares. Evercore restated an “outperform” rating on shares of Edwards Lifesciences in a report on Friday. Barclays raised Edwards Lifesciences to a “strong-buy” rating in a research report on Wednesday, October 7th. Citigroup reiterated a “buy” rating and set a $101.00 price target (up from $96.00) on shares of Edwards Lifesciences in a report on Monday, October 5th. Mizuho upped their price target on Edwards Lifesciences from $100.00 to $105.00 and gave the company an “outperform” rating in a research report on Wednesday, July 15th. Finally, Raymond James Financial upped their price target on Edwards Lifesciences from $100.00 to $103.00 and gave the company an “outperform” rating in a research report on Friday, July 24th. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and seven have given a Hold rating to the company. Based on data from MarketBeat.com, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and an average price target of $100.27.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation (NYSE:EW) is a medical technology company focused on therapies for structural heart disease and critical care. The company develops and manufactures products designed to treat conditions affecting the heart’s valves, including aortic, mitral and tricuspid valve disorders.

Its portfolio includes transcatheter aortic valve replacement systems, transcatheter mitral and tricuspid therapies, surgical heart valves and valve-repair technologies. Edwards also provides related delivery systems and other medical devices used by physicians in minimally invasive and open-heart procedures.

Founded in 1958 by Miles Lowell Edwards, the company is headquartered in Irvine, California, and serves healthcare providers and patients internationally.